Transfer, Molecular Targets and Therapeutics, STB, April 23, 2024 First Patient Administered New Drug for Brain Tumor TreatmentIn an ongoing phase 1 clinical trial targeting malignant glioblastoma, the initial patient has received a dosage of a novel drug candidate, derived from an antibody originating at Helmholtz Munich. This innovative compound, coupled with a…read more
Molecular Targets and Therapeutics, VIRO, March 20, 2024 On the Trail of New VaccinesSeveral research groups at Helmholtz Munich are working on innovative vaccines. Two of them are about to clear a crucial hurdle before approval - fighting the Epstein-Barr virus and Hepatitis B. But how do researchers develop a vaccine?read more
Transfer, Environmental Health, Molecular Targets and Therapeutics, March 11, 2024 Pandemic Preparedness: New High-Tech Laboratory in AugsburgEU Project PerForM-REACT Strengthens Pandemic Preparedness Efforts On March 11, 2024, the inauguration of the expanded safety laboratory in Augsburg marked a milestone within the EU-funded "PerForM-REACT" project, aimed at enhancing pandemic…read more
New Research Findings, Molecular Targets and Therapeutics, IFE, March 06, 2024 Decoding the Language of Epigenetic ModificationsEpigenetic changes play important roles in cancer, metabolic and aging-related diseases, but also during loss of resilience as they cause the genetic material to be incorrectly interpreted in affected cells. A major study by scientists at Helmholtz…read more
Transfer, Molecular Targets and Therapeutics, VIRO, February 22, 2024 Therapeutic Vaccine for Chronic Hepatitis B Enters Clinical TrialTherVacB, a novel therapeutic vaccine to combat chronic hepatitis B, entered the first clinical trial. The vaccine was designed and developed under the leadership of Helmholtz Munich. This phase 1a clinical trial is conducted at the Division of…read more
Featured Publication, Molecular Targets and Therapeutics, January 19, 2024 Epstein-Barr Virus: Molecular Mechanism of Lymphoma Development ElucidatedEpstein-Barr Virus (EBV) is widespread and very contagious: according to the World Health Association more than 90 percent of the global population are infected with this virus throughout their lives. The virus causes B and T cell lymphomas (cancer…read more
New Research Findings, Molecular Targets and Therapeutics, MCD, November 13, 2023 A Rising Star: Inducing Ferroptosis with Innovative Compounds for Cancer TherapyA team of researchers led by Dr. Marcus Conrad from Helmholtz Munich discovered a novel anti-cancer drug, called viFSP1, which sensitizes both murine and human cancer cells to cell death through ferroptosis. Ferroptosis is defined by the…read more
Featured Publication, Molecular Targets and Therapeutics, October 30, 2023 A New Guardian of Ferroptosis: Farnesoid X Receptor Understanding ferroptosis is essential for addressing degenerative diseases and certain cancers. Researchers, led by Dr. Kamyar Hadian from Helmholtz Munich, revealed that the Farnesoid X Receptor (FXR), activated by bile acids, serves as a master…read more
Awards & Grants, Molecular Targets and Therapeutics, VIRO, October 25, 2023 Double Triumph for Helmholtz Munich: Two Researchers Honored with m4 Award from BioMProf. Ulrike Protzer and Dr. Kamyar Hadian and their teams from Helmholtz Munich received the prestigious Bavarian m4 Award, a recognition of their exceptional contributions to the advancement of future medicine and two different groundbreaking…read more
New Research Findings, ICB, Molecular Targets and Therapeutics, August 29, 2023 Aggressive Blood Cancer: Contribution of Enzyme MALT1 UncoveredA team of researchers from Helmholtz Munich in cooperation with scientists at the University Hospital Münster (UKM) has uncovered a new pathway that promotes the growth of aggressive blood cancer, so-called lymphomas. Survival of many lymphomas…read more
Molecular Targets and Therapeutics, August 23, 2023 Molecular Targets & Therapeutics WorkshopThe workshop of the Molecular Targets and Therapeutics centre on July 7th was a great success with over 200 external and internal participants.read more
Molecular Targets and Therapeutics, VIRO, August 21, 2023 Everything you always wanted to know about vaccinationsAn interview with Prof. Ulrike Protzerread more
Molecular Targets and Therapeutics, STB, August 21, 2023 Identification of a key factor for splicing long intronsMutations in FUBP1 cause defective gene regulation in glioma cells Pre-mRNA splicing is an essential step in the maturation of mRNA in which introns are removed and the remaining exons are linked to create a mature mRNA as template for proteins.…read more
Molecular Targets and Therapeutics, STB, August 17, 2023 How to found a biomedical start-up?An interview with Prof. Reinhard Zeidlerread more
Transfer, Molecular Targets and Therapeutics, Pioneer Campus, May 30, 2023 Helmholtz Munich Establishes State-of-the-Art Cryo-Electron Microscopy TechnologyEnabling Breakthroughs in High-Resolution Structural Analysis of Therapeutic Targets and their Visualization in the Native Cellular Contextread more
Featured Publication, Molecular Targets and Therapeutics, STB, May 10, 2023 Structural basis of metabolite transport by the chloroplast outer envelope channel OEP21Triose phosphates (TPs) are the primary products of photosynthetic CO2 fixation in chloroplasts, which need to be exported into the cytosol across the chloroplast inner envelope (IE) and outer envelope (OE) membranes to sustain plant growth.A team…read more
Environmental Health, IEM, Molecular Targets and Therapeutics, VIRO, March 29, 2023 In the Battle Against VirusesDuring the Corona pandemic, experts from Helmholtz Munich helped to bring the situation under control as quickly as possible. Now they are preparing for the possibility of another pandemic: with new high-tech equipment and closely interlinked…read more
New Research Findings, Molecular Targets and Therapeutics, AMIR, July 25, 2022 How Tiny Changes Help T Cells to SurviveResearchers gain a fundamental insight for epitranscriptomics and immune response. The research group around Vigo Heissmeyer and Taku Ito-Kureha of Helmholtz Munich and Ludwig-Maximilians-Universität München has revealed the essential function of m6A…read more
Awards & Grants, Environmental Health, LHI, Molecular Targets and Therapeutics, MCD, July 22, 2022 FERROPath Consortium: Helmholtz Munich Researchers Receive BMBF Research FundingThe German Federal Ministry of Education and Research (BMBF) is funding research of new treatment strategies for preventing tissue ischemia-reperfusion injury (IRI) as part of the FERROPath consortium. Starting in July 2022, the consortium receives…read more
Awards & Grants, Molecular Targets and Therapeutics, VIRO, July 14, 2022 Preventing the Next Pandemic: EU Funds Research Infrastructure in the Munich AreaThe EU grant “PerForM-REACT” supports an infrastructure in the greater Munich area for pandemic management and prevention. Helmholtz Munich will receive new equipment for a biosafety level 3 laboratory where researchers can conduct important studies…read more
Molecular Targets and Therapeutics, STB, June 27, 2022 Hope in the Fight Against ParasitesEvery year, millions of people fall ill with Chagas or sleeping sickness. Both diseases are caused by parasites that are spreading from tropical countries to Europe. Researchers have discovered a weak spot in those parasites, which may be a key to a…read more
New Research Findings, Molecular Targets and Therapeutics, VIRO, February 01, 2022 COVID-19: Breakthrough Infection Can Substitute for a Third Vaccine ShotAccording to a new study led by Ulrike Protzer, a breakthrough infection after two vaccinations achieves the same protective effect as an additional booster vaccination. According to the study by Helmholtz Munich, LMU and TUM, the decisive factor for…read more
Transfer, Awards & Grants, Molecular Targets and Therapeutics, STB, October 12, 2020 Helmholtz Zentrum München Is the Recipient of the 2020 Erwin Schrödinger PrizeResearchers at Helmholtz Zentrum München and the University of Bochum received this year's Erwin Schrödinger Prize in recognition of their efforts to develop a cure for parasitic diseases such as Chagas disease with a new compound. The prize is…read more